Strategic Diagnostics receives initial order for Genomic Antibodies

By Elaine Rigoli

Tampa, Fla., June 14 - Strategic Diagnostics, Inc. said Wednesday that it has received an initial order for Genomic Antibodies from a top-10 pharmaceutical company.

"This initial order serves as a clear indication that world-class, diversified pharmaceutical companies are embracing our ability to provide Genomic Antibodies more quickly than conventional antibodies, while developing Genomic Antibodies to traditionally difficult antigen targets," president and chief executive officer Matthew Knight said in a news release.

"This is the third major pharmaceutical customer to initiate a relationship with Strategic Diagnostics, and although these represent initially small projects, we are increasingly confident in the commercial viability of this capability."

Strategic Diagnostics develops, manufactures and markets biotechnology-based detection solutions across multiple industrial and human health markets.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.